Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.
Audrey Abella, 02 Jul 2020
The highly selective SGLT2 inhibitor bexagliflozin demonstrated significant efficacy and safety in controlling hyperglycaemia, weight, and blood pressure (BP) in patients with type 2 diabetes (T2D) who were at high risk of cardiovascular (CV) events, results of the BEST** trial have shown.
18 Jul 2019
In the treatment of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC), de-escalating dose and volume of radiotherapy (RT) or chemoradiotherapy (CRT) based on response to induction chemotherapy appears to positively affect oncologic outcomes and reduce toxicity, according to data from the phase II OPTIMA trial.

Smoking, unhealthy eating behaviours predict poor adherence to glucose-lowering meds

01 Jul 2020

Medication adherence among patients with diabetes may be negatively influenced by unhealthy lifestyle behaviours such as smoking, skipping breakfast, and eating late in the night, a study suggests.

To examine the clinical variables associated with adherence to oral hypoglycaemic drugs, researchers looked at 8,805 patients (mean age, 53 years; 84 percent male) with diabetes whose medication records were available for at least 1 year. Medication adherence was evaluated by the proportion of days covered (PDC), with PDC of <80 percent defined as nonadherence.

The mean PDC was 80.1 percent, and 32.8 percent of patients were nonadherent. PDC was higher in older patients and lower in smokers. Those with higher PDC tended to have lower levels of HbA1c, low-density lipoprotein cholesterol, and triglycerides.

The PDC for specific oral glucose-lowering drugs was as follows: 82 percent for sulfonylureas, 82 percent for biguanides, 79 percent for thiazolidines, 79 percent for alpha-glucosidase inhibitors, 73 percent for glinides, and 85 percent for DPP-4 inhibitors. The respective rates of nonadherence were 27 percent, 29 percent, 33 percent, 34 percent, 42 percent, and 23 percent.

Logistic analysis found that adherence was associated with older age and taking concomitant medications, whereas nonadherence was linked to skipping breakfast (odds ratio [OR], 0.66, 95 percent confidence interval [CI], 0.57–0.76), late-night eating (OR, 0.86, 95 percent CI, 0.75–0.98), and current smoking (OR, 0.89, 95 percent CI, 0.80–0.99).

In light of the findings, clinicians managing diabetic patients are urged to pay attention to the outlined health-related behaviours to achieve good medication adherence.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.
Audrey Abella, 02 Jul 2020
The highly selective SGLT2 inhibitor bexagliflozin demonstrated significant efficacy and safety in controlling hyperglycaemia, weight, and blood pressure (BP) in patients with type 2 diabetes (T2D) who were at high risk of cardiovascular (CV) events, results of the BEST** trial have shown.
18 Jul 2019
In the treatment of patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC), de-escalating dose and volume of radiotherapy (RT) or chemoradiotherapy (CRT) based on response to induction chemotherapy appears to positively affect oncologic outcomes and reduce toxicity, according to data from the phase II OPTIMA trial.